The test allows oncologists to offer personalised, targeted therapy plan for patients. Credit: fernando zhiminaicela from Pixabay.

Global life sciences company Labcorp has introduced a new liquid biopsy test called Labcorp Plasma Focus.

The new test enables the identification of targeted therapies and improved care for patients suffering from advanced or metastatic solid tumours.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Oncologists can use the test to assess circulating cell-free DNA (cfDNA) released by tumour cells and offer personalised, targeted therapy plans for patients.

Labcorp oncology global enterprise head and senior vice-president Dr Prasanth Reddy said: “The launch of Labcorp Plasma Focus is a critical step in the expansion of Labcorp’s suite of precision oncology tests.

“With a single, minimally invasive blood draw, we are able to detect clinically actionable biomarkers in patients across common cancer types, while reducing the physical burden that testing has on the patient.”

See Also:

Labcorp Plasma Focus test supports providers in identifying biomarkers at an early stage, helping to use available targeted therapies to enhance survival outcomes.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Sequencing cfDNA can help identify key genetic alterations to support the selection of correct therapies for patients with melanoma, oesophageal, breast, colorectal, non-small cell lung, gastroesophageal junction and gastric cancers.

The test is said to complement tissue-based genomic testing, specifically in situations where tissue samples are unavailable or inaccessible.

Labcorp chief medical and scientific officer Dr Brian Caveney said: “Labcorp is focused on delivering critical insights at every stage of care for physicians, patients, cancer care teams and our biopharma partners.

“The development and launch of Labcorp Plasma Focus marks a pivotal moment in the use of technology to enable therapy selection for patients far earlier than previously available, allowing oncologists to better manage the care of their patients.”